English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

urrent therapies for type 2 diabetes are frequently associated with inad- equate control of postprandial hy- perglycemia, weight gain, and, in the case of oral agents, loss of efficacy over time. A better understanding of physiological re- sponses to meals is leading to the devel- opment of new agents whose therapeutic action is based on the enhancement of gastrointestinal hormone action. These therapies are associated with slowing of gastric emptying, stimulation of insulin and inhibition of glucagon secretion, im- proved control of postprandial hypergly- cemia, and control of body weight. This review summarizes several limitations in the treatment of type 2 diabetes and de- scribes the mechanisms of action and clinical data obtained with amylin and glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of diabetes. Despite considerable effort by patients andphysicians,theresultsoftreatingtype2

Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1